Pembrolizumab- induced subacute cutaneous lupus erythematosus in a patient with oropharyngeal squamous cell carcinoma: A case report and literature review
Considering the increasing use of immune checkpoint inhibitors in cancer treatment, our aim is to report a rare cutaneous immune-related adverse event induced by PD-1 inhibitor pembrolizumab and provide a brief overview of pembrolizumab-induced subacute cutaneous lupus erythematosus (SCLE) cases in...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2025.2454073 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832592151038394368 |
|---|---|
| author | Beata Mayer Pavel Babál Lucia Krivošíková |
| author_facet | Beata Mayer Pavel Babál Lucia Krivošíková |
| author_sort | Beata Mayer |
| collection | DOAJ |
| description | Considering the increasing use of immune checkpoint inhibitors in cancer treatment, our aim is to report a rare cutaneous immune-related adverse event induced by PD-1 inhibitor pembrolizumab and provide a brief overview of pembrolizumab-induced subacute cutaneous lupus erythematosus (SCLE) cases in the literature. We report a 67-year-old woman with oropharyngeal squamous cell carcinoma who developed SCLE during treatment with pembrolizumab. After 18 weeks (sixth cycle) of pembrolizumab immunotherapy, a widespread pruritic erythematous rash evaluated as grade 3 immune-related adverse event appeared primarily on the patient's limbs. Histopathological examination and direct immunofluorescence showed characteristic features of SCLE. The patient was treated with oral prednisone 40 mg daily and topical corticosteroids. In 2 weeks, her rash had cleared up significantly and her pruritus had disappeared. SCLE is an infrequent but recognized immune-related adverse event linked to pembrolizumab treatment. |
| format | Article |
| id | doaj-art-6cacb382dbcb49c386eb938614e612a1 |
| institution | Kabale University |
| issn | 2164-5515 2164-554X |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj-art-6cacb382dbcb49c386eb938614e612a12025-01-21T14:13:11ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2025-12-0121110.1080/21645515.2025.2454073Pembrolizumab- induced subacute cutaneous lupus erythematosus in a patient with oropharyngeal squamous cell carcinoma: A case report and literature reviewBeata Mayer0Pavel Babál1Lucia Krivošíková2Department of Dermatovenerology, Faculty of Medicine, Comenius University in Bratislava and University Hospital in Bratislava, Bratislava, SlovakiaInstitute of Pathological Anatomy, Faculty of Medicine, Comenius University in Bratislava and University Hospital in Bratislava, Bratislava, SlovakiaInstitute of Pathological Anatomy, Faculty of Medicine, Comenius University in Bratislava and University Hospital in Bratislava, Bratislava, SlovakiaConsidering the increasing use of immune checkpoint inhibitors in cancer treatment, our aim is to report a rare cutaneous immune-related adverse event induced by PD-1 inhibitor pembrolizumab and provide a brief overview of pembrolizumab-induced subacute cutaneous lupus erythematosus (SCLE) cases in the literature. We report a 67-year-old woman with oropharyngeal squamous cell carcinoma who developed SCLE during treatment with pembrolizumab. After 18 weeks (sixth cycle) of pembrolizumab immunotherapy, a widespread pruritic erythematous rash evaluated as grade 3 immune-related adverse event appeared primarily on the patient's limbs. Histopathological examination and direct immunofluorescence showed characteristic features of SCLE. The patient was treated with oral prednisone 40 mg daily and topical corticosteroids. In 2 weeks, her rash had cleared up significantly and her pruritus had disappeared. SCLE is an infrequent but recognized immune-related adverse event linked to pembrolizumab treatment.https://www.tandfonline.com/doi/10.1080/21645515.2025.2454073Pembrolizumabanti-PD-1-therapyimmunotherapysubacute lupus erythematosuscutaneous lupus erythematosusoropharyngeal squamous cell carcinoma |
| spellingShingle | Beata Mayer Pavel Babál Lucia Krivošíková Pembrolizumab- induced subacute cutaneous lupus erythematosus in a patient with oropharyngeal squamous cell carcinoma: A case report and literature review Human Vaccines & Immunotherapeutics Pembrolizumab anti-PD-1-therapy immunotherapy subacute lupus erythematosus cutaneous lupus erythematosus oropharyngeal squamous cell carcinoma |
| title | Pembrolizumab- induced subacute cutaneous lupus erythematosus in a patient with oropharyngeal squamous cell carcinoma: A case report and literature review |
| title_full | Pembrolizumab- induced subacute cutaneous lupus erythematosus in a patient with oropharyngeal squamous cell carcinoma: A case report and literature review |
| title_fullStr | Pembrolizumab- induced subacute cutaneous lupus erythematosus in a patient with oropharyngeal squamous cell carcinoma: A case report and literature review |
| title_full_unstemmed | Pembrolizumab- induced subacute cutaneous lupus erythematosus in a patient with oropharyngeal squamous cell carcinoma: A case report and literature review |
| title_short | Pembrolizumab- induced subacute cutaneous lupus erythematosus in a patient with oropharyngeal squamous cell carcinoma: A case report and literature review |
| title_sort | pembrolizumab induced subacute cutaneous lupus erythematosus in a patient with oropharyngeal squamous cell carcinoma a case report and literature review |
| topic | Pembrolizumab anti-PD-1-therapy immunotherapy subacute lupus erythematosus cutaneous lupus erythematosus oropharyngeal squamous cell carcinoma |
| url | https://www.tandfonline.com/doi/10.1080/21645515.2025.2454073 |
| work_keys_str_mv | AT beatamayer pembrolizumabinducedsubacutecutaneouslupuserythematosusinapatientwithoropharyngealsquamouscellcarcinomaacasereportandliteraturereview AT pavelbabal pembrolizumabinducedsubacutecutaneouslupuserythematosusinapatientwithoropharyngealsquamouscellcarcinomaacasereportandliteraturereview AT luciakrivosikova pembrolizumabinducedsubacutecutaneouslupuserythematosusinapatientwithoropharyngealsquamouscellcarcinomaacasereportandliteraturereview |